672324-83-3 Usage
Uses
Used in Pharmaceutical Research:
(4-Aminomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester is used as a building block in pharmaceutical research for the synthesis of novel pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, (4-Aminomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester is used as an intermediate compound to facilitate the formation of more complex molecules. Its reactivity and stability make it a valuable component in the synthesis of various organic compounds.
Used in Drug Development:
(4-Aminomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester is also used in the development of new drugs targeting specific biological pathways. Its potential therapeutic applications are being studied, and it may contribute to the creation of innovative treatments for various diseases and conditions.
Used in the Chemical Industry:
Within the chemical industry, (4-Aminomethyl-pyridin-2-yl)-carbamic acid tert-butyl ester may be employed as a reactant or catalyst in various chemical processes, contributing to the production of a wide range of products.
Check Digit Verification of cas no
The CAS Registry Mumber 672324-83-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,2,3,2 and 4 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 672324-83:
(8*6)+(7*7)+(6*2)+(5*3)+(4*2)+(3*4)+(2*8)+(1*3)=163
163 % 10 = 3
So 672324-83-3 is a valid CAS Registry Number.
672324-83-3Relevant academic research and scientific papers
PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS
-
Page 96-97, (2008/06/13)
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
